Recombinant vaccine-derived poliovirus in Madagascar
| Autor: | Philippe Mauclère, Bakolalalo Randriamanalina, Sophie Guillot, Jean Balanant, Richter Razafindratsimandresy, Francis Delpeyroux, Mala Rakoto-Andrianarivelo, Dominique Rousset |
|---|---|
| Přispěvatelé: | Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Ministry of Health, Ministry of Health [Mozambique], Biologie des Virus entériques (BVE), Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] |
| Předmět: |
Male
MESH: Sequence Analysis DNA Epidemiology lcsh:Medicine medicine.disease_cause MESH: Madagascar MESH: Child Child ComputingMilieux_MISCELLANEOUS Enterovirus Recombination Genetic Genetics 0303 health sciences Poliovirus Vaccination MESH: Enterovirus Dispatch Nucleic acid sequence MESH: Infant 3. Good health Poliovirus Vaccines Infectious Diseases GenBank [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Female MESH: Recombination Genetic Restriction fragment length polymorphism MESH: Poliovirus Vaccines Polymorphism Restriction Fragment Length MESH: Poliovirus Microbiology (medical) Biology Coxsackievirus lcsh:Infectious and parasitic diseases 03 medical and health sciences medicine Madagascar Humans lcsh:RC109-216 030304 developmental biology MESH: Humans 030306 microbiology MESH: Polymorphism Restriction Fragment Length lcsh:R Infant Outbreak Sequence Analysis DNA MESH: Vaccination biology.organism_classification Virology MESH: Male Restriction enzyme MESH: Poliomyelitis MESH: Female Poliomyelitis |
| Zdroj: | ResearcherID Emerging Infectious Diseases, Vol 9, Iss 7, Pp 885-887 (2003) Emerging Infectious Diseases Emerging Infectious Diseases, 2003, 9 (7), pp.885-7. ⟨10.3201/eid0907.020692⟩ Emerging Infectious Diseases, Centers for Disease Control and Prevention, 2003, 9 (7), pp.885-7. ⟨10.3201/eid0907.020692⟩ |
| ISSN: | 1080-6040 1080-6059 |
| DOI: | 10.3201/eid0907.020692⟩ |
| Popis: | To the Editor: Between October 2001 and April 2002, five cases of acute flaccid paralysis associated with vaccine-derived poliovirus (VDPV) type 2 isolates were reported in the southern province of the Republic of Madagascar. The first patient, an 11-year-old child from the urban district of Toliara, first experienced paralysis on October 29, 2001. Three other children, 6, 9, and 14 months of age from Ebakika village, in a rural district of Taolagnaro (250 miles east of Toliara), showed signs of poliomyelitis between March 21 and March 26, 2002. The last case-patient, a 20-month-old child from Ambanihazo village (6 miles north of Ebakika), came into contact with one of the three case-patients in Ebakika in March 2002, and symptoms developed on April 12, 2002 (1). None of the patients had been fully vaccinated against poliomyelitis. Nine type 2 poliovirus (PV) strains were isolated. A restriction fragment length polymorphism (RFLP) assay, with three different genomic regions amplified by reverse transcription–polymerase chain reaction (RT-PCR) and four different restriction enzymes (HinfI, DpnII, RsaI, and DdeI) were used to characterize the PV isolates at the molecular level (2). The RFLP profiles of all of the isolates in the two capsid protein regions were identical to that of the type 2 strain of the oral polio vaccine (OPV) in the VP1-2A region (nucleotides 2,872 to 3,647) but slightly different in the VP3-VP1 region (nucleotides 1,915 to 2,883). The observed differences allowed us to distinguish two groups (isolates from Toliara and isolates from Taolagnaro) and two subgroups (isolates from March and isolates from April). The RFLP profiles of isolates in the noncapsid region, at the 3′-terminal end of the genome (polymerase 3D and 3′ noncoding regions: nucleotides 6,535 to 7,439) also confirmed the presence of two separate groups. These last profiles were completely different from those of the three reference vaccine strains, suggesting recombination with other enteroviruses. Partial genomic sequencing confirmed these observations. The entire VP1 region (903 nucleotides) of the type 2 PV strains from Toliara and Taolagnaro differed from the type 2 OPV strain by 1% and 2.5% nucleotides, respectively. This difference may indicate that the two strains had been multiplying or circulating for approximately 1 and 2.5 years, respectively. Taolagnaro strains are closely related to each other ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|